Pharmaceutical Executive Issue Alert Having trouble viewing this email? Click here
Web Version | Share with a colleague | View Digital Edition | Subscribe
In our August issue of Pharmaceutical Executive
FEATURES

Gene Therapy
Mapping Out the Future of Cell and Gene Therapy
 Lital Aravot
The cell and gene therapy space remains fertile territory for growth, exploration, and discovery. How applying a data-driven model may be the best way to approach this complex ecosystem and assess the innovations of tomorrow.
Download the digital issue

ADVERTISEMENT
Managing Global Regulatory Complexity: Clinical Trial Transparency, Reporting and Real-time Data Driven Compliance
Wednesday, August 14, 2019 at 12pm EDT | 9am PDT | 5pm BST | 6pm CEST
Register Now
Gene Therapy
High-Stakes Manufacturing: Mitigating the Risks
Mo Heidaran, Richard Macaulay
How to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.
Download the digital issue
Gene Therapy
Routes to Exclusivity in Cell-Based Therapy Development
 Brian Reese, Charles Lyon
Outlining the critical steps for companies in controlling market exclusivity for their gene therapy products.
Download the digital issue
Interview
The Call to Cure: Geoff MacKay, AVROBIO
 Julian Upton
Pharm Exec speaks with Geoff MacKay, CEO of AVROBIO, about the company's mission to advance potentially curative lentiviral-based gene therapies and moving gene therapy into the mainstream.
Download the digital issue

ALSO IN THIS ISSUE
 Scott Gottlieb: A Look Back & Forward on Innovation
Lisa Henderson
In a sit-down with editors from our group publications, former FDA Commissioner Scott Gottlieb chatted with Pharm Exec on several topics, including the evolution of pricing and reimbursement for novel therapies–and the access fixes needed for future  …Read more

FDA Faces 'Explosion' in Growth of Gene Therapies
Jill Wechsler
Agency focused on advancing testing and production methods, seeking input from other regions on common approaches  …Read more

Gene Therapy: How 'Advanced' is Europe?
Reflector
Exploring the EU's struggles and new efforts in promoting cell and gene drugs  …Read more

Four Takeaways from the Zolgensma Pricing Storm
Hervé Lilliu
Novartis' May announcement of the list price of its new gene therapy for spinal muscular atrophy, Zolgensma, sparked a plethora of heated reactions. But was this a storm in a teacup or a tropical cyclone?  …Read more

 
Download the
issue:
 
image
 
WEBCASTS
Managing Global Regulatory Complexity: Clinical Trial Transparency, Reporting and Real-time Data Driven Compliance
AI-powered Biomedical Literature Discovery supporting Science-based Business Decisions
Patient Adherence: A Hard Pill to Swallow?
Using Real-World Evidence for U.S. Regulatory Decision-Making: What Pharma Needs to Know
Japan Market Entry: How to Navigate the Clinical Development Regulatory Environment and Best Methods to Utilize Opportunities
Patient Assistance Centers of Excellence: The Next Generation of Brand Support

Pharmaceutical Executive is free to qualified subscribers. To subscribe, click here.

Click here to contact the Pharmaceutical Executive sales team.
Twitter LinkedIn